From The Stage

A Dose of Pharma and Biotech News: September 19, 2018

Posted by / / BioAgilytix Insight, Industry Update

To keep up with the rapidly evolving field of drug development, we must stay on the pulse of bioanalytical innovation. Our latest blog summarizes some of the latest industry articles our team has found noteworthy.

The Evolution of Bioanalytical Outsourcing Partnerships

Posted by / / CRO Selection, Industry Update

Bioanalytical outsourcing has changed dramatically in the past 30 years, which isn’t surprising when you consider how our economy, the healthcare market, technology, and drugs themselves have changed in that same period. To fully understand how we have arrived, as an industry, at a place where outsourcing is vital to our collective success, it is helpful to look back at where we started.

Attracting and Retaining Scientific Talent in a Complex, Competitive Industry

Posted by / / BioAgilytix Insight, Industry Update

Finding the right talent is challenging for any organization in any industry, but when you work in a complex field that requires highly skilled workers, it can be even more difficult. BioAgilytix’s CEO discusses the critical nature of hiring for a CRO, and approaches to attracting and retaining top scientific talent in a competitive industry.

Biologics Market Growth Demands Quality Science that Can Keep Pace

Posted by / / CRO Selection, Industry Update

It is anticipated that biologics will comprise 50% of the top 100 drugs by 2021. But, given the structural complexities of large molecule drugs, adherence to stringent quality standards will be a necessary part of effectively bringing these innovations to market. We discuss why it will be essential for pharma and biotech companies to align with outsourced partners that can deliver the quality science large molecule bioanalysis demands.

Key Takeaways from the 14th Annual PEGS Summit

Posted by / / BioAgilytix Insight, Industry Update

Our team recently attended the 14th Annual PEGS Summit to participate in discussions around advancements in biotherapeutic protein drug development and how they impact the work we do with large molecule biologics. From improving efficacy of CAR-T cell therapies to managing the challenges of immunogenicity testing, we’ve summarized the most compelling insights we gained at this year’s event.

Key Takeaways from the 12th Workshop on Recent Issues in Bioanalysis (WRIB)

Posted by / / BioAgilytix Insight, Industry Update

Scientists from BioAgilytix recently attended the 12th WRIB in Philadelphia, PA. Meeting new contacts in the industry and taking part in discussions concerning the most innovative topics in bioanalysis, biomarkers, and immunogenicity was a genuinely valuable and enjoyable experience. We recap the topics that our team found to be most interesting at WRIB this year.

A Dose of Pharma and Biotech News: March 7, 2018

Posted by / / BioAgilytix Insight, Industry Update

BioAgilytix is committed to keeping on the pulse of bioanalytical innovation across the pharmaceutical and biotechnology industries. To that end, we’d like to share some of the industry headlines we’ve been most interested in recently.

The Scientific Topics that Shaped Our 2017

Posted by / / BioAgilytix Insight, Industry Update

Throughout 2017, BioAgilytix scientists continued to establish themselves as thought leaders in the industry through the publication of blogs and industry articles, covering topics from biomarkers and immunogenicity to investing in bioanalytical technology. We thank you for engaging with our posts this year, and we look forward to sharing more about our rapidly changing industry with you in 2018. Take a look back at some of 2017’s hot topics in bioanalysis through some of our favorite content pieces: 1. Immuno-oncology: Advancing Innovative Therapeutic Options for Treating Human Cancers Learn more…

Modern Challenges of Single and Multiplex Biomarker Validation

Posted by / / Biomarkers, Industry Update

Biomarker validation can be confusing. We constantly hear about qualification versus validation, fit-for-purpose validation, and context of use. Due to the ‘grey area’ nature of biomarker work, many companies interpret these concepts and approaches differently. As scientists working on biomarker projects, we have to deal with a lot of variability between reagent and kit lots, high or low biomarker endogenous levels, and how to precisely assess antibody specificity in commercial kits, among other things. In a perfect world, we would have decisive guidance on how to manage all of these…